74|10000|Public
25|$|On 18 March 2013, in a {{very unusual}} move, the {{prosecution}} also applied for a <b>trial</b> <b>de</b> <b>novo,</b> based on exculpating evidence that had surfaced only after the original trial.|$|E
25|$|In {{a motion}} before the Northwest Territories Territorial Court, counsel for Drybones argued that since their client did not {{understand}} English, he {{did not understand}} the nature of the proceedings, rendering his guilty plea invalid and subject to withdrawal. The motion was granted and the guilty plea was revoked by Drybones, the Court ordering a <b>trial</b> <b>de</b> <b>novo.</b>|$|E
25|$|Simpson and his {{co-defendant}} {{were found}} guilty of all charges on October 3, 2008. On October 10, 2008, Simpson's counsel moved {{for a new trial}} (<b>trial</b> <b>de</b> <b>novo)</b> on grounds of judicial errors and insufficient evidence. Simpson's attorney announced he would appeal to the Nevada Supreme Court if Judge Glass denied the motion. The attorney for Simpson's co-defendant, C. J. Stewart, petitioned for a new trial, alleging Stewart should have been tried separately and cited possible misconduct by the jury foreman.|$|E
5000|$|LCP-Tacro ({{tacrolimus}}) is a once-daily dosage {{version of}} tacrolimus for prevention of rejection in organ transplant patients in two Phase 3 clinical trials in kidney transplant patients. The first study in stable transplant patients showed that LCP-Tacro was non-inferior in efficacy and safety compared to twice-daily tacrolimus (Prograf®) REF. The second Phase 3 clinical <b>trial</b> in <b>de</b> <b>novo</b> patients is ongoing. [...] A Phase 3b clinical trial evaluating whether patients experiencing symptomatic tremor on twice-daily tacrolimus demonstrate {{improvement in their}} tremors when switched to LCP-Tacro is ongoing.|$|R
40|$|The {{gastropod}} Patella vulgata {{is abundant}} on rocky shores in Northern Europe {{and a significant}} grazer of intertidal algae. Here we report the application of Illumina sequencing to develop a transcriptome from the adult mantle tissue of P. vulgata. We obtained 47, 237, 104 paired-end reads of 51  bp, <b>trialled</b> <b>de</b> <b>novo</b> assembly methods and settled on the additive multiple K method followed by redundancy removal as resulting in the most comprehensive assembly. This yielded 29, 489 contigs of at least 500  bp in length. We then used three methods to search for candidate genes relevant to biomineralisation: searches via BLAST and Hidden Markov Models for homologues of biomineralising genes from other molluscs, searches for predicted proteins containing tandem repeats and searches for secreted proteins that lacked a transmembrane domain. From {{the results of these}} searches we selected 15 contigs for verification by RT-PCR, of which 14 were successfully amplified and cloned. These included homologues of Pif- 177 /BSMP, Perlustrin, SPARC, AP 24, Follistatin-like and Carbonic anhydrase, as well as three containing extensive G-X-Y repeats as found in nacrein. We selected two for further verification by in situ hybridisation, demonstrating expression in the larval shell field. We conclude that <b>de</b> <b>novo</b> assembly of Illumina data offers a cheap and rapid route to a predicted transcriptome that {{can be used as a}} resource for further biological study...|$|R
5000|$|In some {{municipalities}} of Colorado there are municipal courts, {{which are not}} part of the state court system. Municipal court jurisdiction is limited to municipal ordinance cases, including traffic violations imposed under municipal ordinances rather than state statutes, which have maximum penalties similar to those of state law petty offenses. [...] These courts have no statutory jurisdiction over other classes of cases, although municipal courts do have inherent procedural powers associated with their status as a court, such as contempt of court powers and powers related to the calling and compensation of jurors. Some municipal courts are courts of record which can impose greater sanctions for ordinance violations and are subject to appellate review in a manner similar to state courts. Other municipal courts are courts not of record, which can impose only less severe sanctions for ordinance violations, whose decisions are appealed through <b>trials</b> <b>de</b> <b>novo</b> in the appellate court. A small number of municipal courts in Colorado have been granted civil jurisdiction in certain ordinance cases, such as cases involving land use, under municipal home rule powers, in addition to quasi-criminal jurisdiction.|$|R
25|$|Some {{state court}} systems have promulgated court-ordered arbitration; family law (particularly child custody) {{is the most}} {{prominent}} example. Judicial arbitration is often merely advisory dispute resolution technique, serving {{as the first step}} toward resolution, but not binding either side and allowing for <b>trial</b> <b>de</b> <b>novo.</b> Litigation attorneys present their side of the case to an independent teritary lawyer, who issues an opinion on settlement. Should the parties in question decide to continue to dispute resolution process, there can be some sanctions imposed from the initial arbitration per terms of the contract.|$|E
25|$|Non-Binding Arbitration is {{a process}} which is {{conducted}} {{as if it were}} a conventional arbitration, except that the award issued by the tribunal is not binding on the parties, and they retain their rights to bring a claim before the courts or other arbitration tribunal; the award is in the form of an independent assessment of the merits of the case, designated to facilitate an out-of-court settlement. State law may automatically make a non-binding arbitration binding, if, for example, the non-binding arbitration is court-ordered, and no party requests a <b>trial</b> <b>de</b> <b>novo</b> (as if the arbitration had not been held).|$|E
25|$|In the <b>trial</b> <b>de</b> <b>novo,</b> {{the crown}} called six witnesses, {{including}} the Royal Canadian Mounted Police (RCMP) Constables {{and the wife}} of the hotel manager who had found Drybones. The crown also produced Joe Sangris as one of their witnesses, a former chief and leader of the Indian village at Yellowknife for 16 years. Mr. Sangris testified that he had known Drybones from his birth, as well as his wife and his father. Mr. Sangris also testified that Drybones received treaty money once a year. Another crown witness included David George Greyeyes, once the regional director of Indian affairs. Mr. Greyeyes was the officer charged with the maintenance of Indian records, contractual obligations and the execution of federal treaties involving Indians. Mr. Greyeyes produced official records of a Mr. Drybones, married to Madeline Crapeau with no children. Both Mr. Greyeyes and Mr. Sangris also testified that there were no Indian reserves in the Northwest Territories.|$|E
50|$|In {{terms of}} section 105A(6)(b), {{if the court}} is not {{satisfied}} that the accused is guilty, or if the accused does not admit any allegation in the charge, or has incorrectly admitted such, or if the court is satisfied, for any other reason, that the plea should not stand, then court will record a {{plea of not guilty}} and order the <b>trial</b> to start <b>de</b> <b>novo</b> before another presiding officer (unless the accused waives such right to another presiding officer).|$|R
40|$|Purpose Clinical trials {{data from}} National Cancer Institute (NCI) -funded {{cooperative}} oncology group trials could {{be enhanced by}} merging with external data sources. Merging without direct patient identifiers would provide additional patient privacy protections. We sought to develop and validate a matching algorithm that uses only indirect patient identifiers. Methods Wemerged the data from two Phase III Children’s Oncology Group (COG) <b>trials</b> for <b>de</b> <b>novo</b> acute myeloid leukemia (AML) with the Pediatric Health Information Systems (PHIS). We developed a stepwise matching algorithm that used indirect identifiers including treatment site, gender, birth year, birth month, enrollment year and enrollment month. Results from the stepwise algorithm were compared against the direct merge method that used date of birth, treatment site, and gender. The indirect merge algorithm was developed on AAML 0531 and validated on AAML 1031...|$|R
5000|$|Cox's outside {{activities}} {{shifted from}} arbitration to government reform and appellate advocacy. In 1975, court reform {{was a top}} priority in Massachusetts where criminal cases had backlogged the system, which (because they required priority) resulted in even greater congestion of civil cases. Cox was appointed to a Massachusetts Bar committee to study the problem. in February 1976 Governor Michael Dukakis appointed Cox to head the 20 member Governor's Select Committee on Judicial Needs to make recommendations. In December the committee issued the Cox-drafted report, entitled [...] "Report on the State of the Massachusetts Court." [...] The Report's most important recommendations were a structuring of the District Courts, state assumption of the administrative costs of the courts, placing management of the court system {{in the hands of}} the chief justice of the Supreme Judicial Court, abolition of <b>trials</b> <b>de</b> <b>novo</b> in appeals from the District Court and tightening of the rules for remand and continuances. Despite the fact that the Governor made judicial reform along the lines of the Cox report his [...] "top" [...] legislative priority for 1976, and despite the fact that the proposal was supported by the newspapers of the state, and despite intense lobbying efforts by Cox himself (not only in testimony before the legislatures but also in numerous speaking events throughout the state) over the course of 1976, the legislation ultimately ran out of time in the 1977 legislative session. In the next session the bill was drastically revised, but ultimately retained the state take-over of funding and implemented some centralization and coordination.|$|R
25|$|On 19 February 2013, Strate {{applied for}} a <b>trial</b> <b>de</b> <b>novo</b> based on {{evidence}} that the presiding judge had committed numerous instances of perversion of justice against Mollath in the case. According to Strate, the judge was responsible for Mollath's detention for almost three weeks without disclosure of the charges or presentation to a judge, failure to respond to Mollath's complaints or forward them to the higher court that should have decided them, manipulation of the court's composition, obvious misrepresentations in {{the reasons for the}} judgment, and unconscionable refusal to discharge Mollath's assigned counsel in spite of many petitions to do so, followed by use of said counsel as a witness against his own client. To prevent duplication of effort with the prosecution, which was preparing a similar application of its own, the application was based exclusively on material that was, or should have been, available to the original court {{at the time of the}} original verdict. The application was debated in the legal committee of the Bavarian Parliament.|$|E
25|$|Inside the PȚB, Pântea was {{loyal to}} Inculeț, and {{fought against the}} factions headed by Pan Halippa and Pelivan. He edited the party's Basarabia newspaper, where he {{launched}} tirades against Halippa, and again rose to a leadership position after Halippa's expulsion. Pântea followed Inculeț into Romania's National Liberal Party (PNL), and became deputy leader of the group's Bessarabian section. This affiliation got him elected into the Romanian Assembly of Deputies (lower chamber of Parliament), the first of ten consecutive terms. Pântea was nevertheless considered suspect by the Romanian establishment, who believed him a man of left-wing sympathies and a promoter of communist literature. He was attorney for the group of Bessarabian communists, led by Pavel Tcacenco, who had agitated against the Romanian state. The pro bono activity was largely successful: Tcancenco and other three men were found guilt of sedition, {{and sentenced to death}} in absentia; 65 detainees were acquitted; 39 others were set free after <b>trial</b> <b>de</b> <b>novo.</b> This implied placing himself against the PNL government, particularly since Pântea reported to the world on the alleged the abuse of power by Romanian administrators in Bessarabia. His intervention in Parliament prompted the Interior Ministry (headed by Nicolae L. Lupu) to sack the leadership of Siguranța police in Chișinău.|$|E
500|$|He {{ruled that}} it was unconstitutional to require that a jury be {{unanimous}} in its finding of circumstances mitigating against determining a sentence of death. Eliot Grossman and Marlene Kamish, attorneys for Abu-Jamal, criticized the ruling {{on the grounds that}} it denied the possibility of a <b>trial</b> <b>de</b> <b>novo,</b> at which they could introduce evidence that their client had been framed. Prosecutors also criticized the ruling; Officer Faulkner's widow Maureen described Abu-Jamal as a [...] "remorseless, hate-filled killer" [...] who would [...] "be permitted to enjoy the pleasures that come from simply being alive" [...] on the basis of the judgment. Both parties appealed.|$|E
50|$|Two anticancer agents, Onrigin (laromustine), {{formerly}} cloretazine (VNP40101M), and Triapine, a ribunucloetide reductase inhibitor {{similar to}} hydroxyurea, were in human clinical trials. A novel alkylating agent, Onrigin was evaluated in a Phase 2 <b>trial</b> in elderly <b>de</b> <b>novo</b> poor-risk {{acute myeloid leukemia}} (AML). In addition, several trials of Onrigin were conducted in elderly patients with AML and myelodysplastic syndrome (MDS) in combination with cytarabine, and in patients with brain tumors in combination with temozolomide. After Onrigin {{was rejected by the}} Food and Drug Administration for an AML indication in 2009 due to an unfavorable risk-benefit profile, the company became defunct.|$|R
40|$|Abstract—In 1993, {{the last}} AAN Practice Parameter on medical {{treatment}} of Parkinson’s disease (PD) concluded that levodopa {{was the most}} effective drug for management of this disorder. Since then, {{a number of new}} compounds including non-ergot dopamine agonists (DA) and sustained-release levodopa have been released and studied. Thus, the issue of treatment in <b>de</b> <b>novo</b> PD patients warrants reexamination. Specific questions include: 1) does selegiline offer neuroprotec-tion; 2) what is the best agent with which to initiate symptomatic treatment in <b>de</b> <b>novo</b> PD; and 3) is there a benefit of sustained release levodopa over immediate-release levodopa? Using evidence-based principles, a literature review using MEDLINE, EMBASE, and the Cochrane Library was performed to identify all human <b>trials</b> in <b>de</b> <b>novo</b> PD between 1966 and 1999. Only articles that fulfilled class I or class II evidence were included. Based on this review, the authors conclude: 1) Selegiline has very mild symptomatic benefit (level A, class II evidence) with no evidence for neuroprotective benefit (level U, class II evidence). 2) For PD patients requiring initiation of symptomatic therapy, either levodopa or a DA can be used (level A, class I and class II evidence). Levodopa provides superior motor benefit but is associated with a higher risk of dyskinesia. 3) No evidence was found that initiating treatment with sustained-release levodopa provides an advantage over immediate-release levodopa (level B, class II evidence) ...|$|R
40|$|Background. FTY 720 has {{recently}} demonstrated a similar efficacy in prevention of acute graft rejection compared with mycophenolate mofetil (MMF) {{in a large}} phase III <b>trial</b> of <b>de</b> <b>novo</b> renal transplant recipients. Creatinine clearance, however, was signifi-cantly lower in FTY 720 -treated patients. In the present study, we examined the impact of FTY 720 on vascular function in a subgroup of patients of this trial. Methods. Eighteen patients (12 FTY 720, 6 MMF) agreed to be enrolled for an analysis of vascular function. Vascular measurements were performed 1. 5 years post-transplant and were repeated 3 months after conversion of the patients from FTY 720 to MMF. Arterial stiffness was assessed as augmentation index (AI 75); endothelium-dependent and-independent vasodilation were measured sonographically as flow-mediated dilation (FMD) and as vasodilation after application of glyceroltrinitrate (GTN). Results. Conversion from 2. 5 mg FTY 720 to MMF led to a significant improvement of FMD (5. 40 1. 84 v...|$|R
2500|$|In October 1955, Gherman Pântea was {{included}} in an amnesty decreed by the Romanian communist authorities, as the early sign of a reluctant liberalization. In January of the next year, he was even partially rehabilitated during a <b>trial</b> <b>de</b> <b>novo</b> for some 800 sentenced war criminals. After gathering evidence and testimonials from Soviet nationals, he took his case to the Supreme Tribunal, which concluded that his sentencing as a [...] "war criminal" [...] was illegal (while finding little evidence that his were crimes [...] "against the working class"). However, the Securitate still kept a file on Pântea, keeping {{him and his family}} under constant surveillance. At a time when repression was organized against the Bessarabian refugees, its staff gathered data according to which Pântea was capable of organizing Bessarabian resistance in Romania-proper. With noted help from the Soviet KGB and a female Soviet envoy (codenamed Valeria), the secret police began re-investigating Pântea's various activities in politics. The Securitate archives also show that Securitate men approached the former Bessarabian Director with an offer to become their informant, but register Pântea's blunt refusal, even after intimidation.|$|E
2500|$|In {{legal systems}} based on English tradition, {{findings}} of fact by a jury, and jury conclusions that could be supported by jury {{findings of fact}} even if the specific factual basis for the verdict is not known, are entitled to great deference on appeal. [...] In other legal systems, it is generally possible for an appellate court to reconsider both findings of fact and conclusions of law made in the trial court, and in those systems evidence may be presented to appellate courts in {{what amounts to a}} <b>trial</b> <b>de</b> <b>novo</b> (new trial) of appealed findings of fact. [...] The finality of trial court findings of fact in legal systems based on the English tradition has major impact on court procedure in these systems. [...] This makes it imperative that lawyers be highly prepared for trial because errors and misjudgments related to the presentation of evidence at trial to a jury cannot generally be corrected later on appeal, particularly in court systems based on the English tradition. [...] The higher the stakes, the more this is true. [...] Surprises at trial are much more consequential in court systems based on the English tradition than they are in other legal systems.|$|E
5000|$|In law, the {{expression}} <b>trial</b> <b>de</b> <b>novo</b> means a [...] "new trial" [...] {{by a different}} tribunal (de novo is a Latin expression meaning [...] "afresh", [...] "anew", [...] "beginning again", hence the literal meaning [...] "new trial"). A <b>trial</b> <b>de</b> <b>novo</b> is usually ordered by an appellate court when the original trial failed to make a determination in a manner dictated by law.|$|E
40|$|The {{subject matter}} of the article is the {{regulation}} of the Constitution of Polish People's Republic, the Constitutional Tribunal Act (CT) of 29 Apr. 1985 and the resolution of the Polish Seym of 31 Jul. 1985 on the specific proceedings before the CT, concerning several problems marked in the title. The author advocates his opinion in the following questions: 1. Relation of the quoted resolution to the CT Act. The author maintains that the regulation of the resolution should be contained in the Act. 2. Membership and the mode of constituting the CT, conditions to be fulfilled by the candidates to become appointed members, possibilities of revokinf the CT judges. 3. Questions of independence of the judges, their subordination and the judicial immunity, the author advocates here that contrary to the explicit Constitutional regulation, the CT judges are subordinated not only to the Constitution but also to parliamentary statutes and resolutions. 4. The range of subjects entitled to apply to the CT to decide on the legality of regulation, and the formal requirements concerning the said applications; the author advocates that citizens are not ellegible to apply directly to the CT but they can influence the activity of the state organs and social organizations. 5. The range of subjects entitled to address legal queries to the CT, the mode of proceedings, deciding and effects of the CT decisions in that scope. 6. Next, trails before the CT, benches, final character of the CT decisions, possibility of <b>trials</b> <b>de</b> <b>novo</b> in cases decided by the CT in the full composition of its bench, character of the general meeting of the CT judges. 7. The final part dwells on the CT decisions, their formal requirements, legal effects of the decisions and the mode of their execution. Digitalizacja i deponowanie archiwalnych zeszytów RPEiS sfinansowane przez MNiSW w ramach realizacji umowy nr 541 /P-DUN/ 201...|$|R
40|$|Proteinuria {{has been}} {{reported}} in several papers after conversion from calcineurin inhibitors to Sirolimus (SRL), but this complication has not been analyzed in randomized clinical <b>trials</b> using <b>de</b> <b>novo</b> SRL. It is not known whether <b>de</b> <b>novo</b> use of SRL is a risk factor for proteinuria. We analyzed a series of patients included in a big multicenter randomized trial (RMR trial) corresponding to all patients in Spain and Portugal with respect to this issue. We retrospectively evaluated 24 -hour proteinuria in all the patients during the study period (5 years postransplant) for comparison between treatment arms group A, continuous cyclosporine (CyA) + SRL and group B SRL with CyA elimination at 3 months postransplant. The elimination of CyA after the third month was not followed by significant changes in proteinuria. Nevertheless, during the last year of follow-up (between 48 and 60 months postransplant) an impressive increase in proteinuria was observed in group A. This surprising finding seemed to be a consequence of a protocol amendment that recommended CyA elimination in patients of group A, due to poorer results in the intermediate analysis of the trial. This fact suggests that the hemodynamic changes induced by elimination of the vasoconstrictor CyA might be responsible for the proteinuria but only in the long term probably when significant pathological lesions are already present. This finding argues for earlier conversion...|$|R
40|$|AIM Cyclosporine (CsA), dosed {{to achieve}} C 2 targets, {{has been shown}} to provide safe and efficacious {{immunosuppression}} when used with a mycophenolate and steroids for <b>de</b> <b>novo</b> kidney transplant recipients. This study examined whether use of enteric-coated mycophenolate sodium (EC-MPS) together with basiliximab and steroids would enable use of CsA dosed to reduced C 2 targets in order to achieve improved graft function. METHODS Twelve-month, prospective, randomized, open-label <b>trial</b> in <b>de</b> <b>novo</b> kidney transplant recipients in Australia. Seventy-five patients were randomized to receive either usual exposure (n[*]=[*] 33) or reduced exposure (n[*]=[*] 42) CsA, EC-MPS 720 [*]mg twice daily, basiliximab and corticosteroids. RESULTS There {{was no significant difference in}} mean Cockcroft-Gault CrCl (creatinine clearance) (60. 2 [*]±[*] 17. 6 [*]mL/min per 1. 73 [*]m 2 vs 63. 2 [*]±[*] 24. 3, P[*]=[*] 0. 64 for usual versus reduced exposure respectively) at 6 months. There was no significant difference between treatment groups in the incidence of treatment failure defined as biopsy proven acute rejection, graft loss or death (secondary endpoint: 30. 3 % full exposure vs 35. 7 % reduced exposure). At 12 months the incidence of overall adverse events was the same in both groups. CONCLUSION This exploratory study suggests <b>de</b> <b>novo</b> renal transplant patients can safely receive a treatment regimen of either full or reduced exposure CsA in combination with EC-MPS, corticosteroids and basiliximab, with no apparent difference in efficacy or graft function during the first year after transplant. Steve Chadban, Josette Eris, Graeme Russ, Scott Campbell, Jeremy Chapman, Bruce Pussell, Paul Trevillian, Francesco Ierino, Napier Thomson, Brian Hutchison, Ashley Irish, Chad Woodcock, Nicol Kurstjens and Rowan Walker: The Myproms Au Study Grou...|$|R
50|$|A {{new trial}} {{in which all}} issues are {{reviewed}} {{as if for the}} first time is called a <b>trial</b> <b>de</b> <b>novo.</b>|$|E
50|$|Education reform - HB 1380 {{eliminated}} {{the ability of}} public school teachers to appeal any termination to state district courts as a <b>trial</b> <b>de</b> <b>novo.</b>|$|E
50|$|On 18 March 2013, in a {{very unusual}} move, the {{prosecution}} also applied for a <b>trial</b> <b>de</b> <b>novo,</b> based on exculpating evidence that had surfaced only after the original trial.|$|E
40|$|Everolimus 1. 5 or 3 mg/day was {{compared}} with mycophenolate mofetil (MMF) 2 g/day in a randomized, multicenter 36 -month <b>trial</b> in <b>de</b> <b>novo</b> renal allograft recipients (n = 588) receiving cyclosporine microemulsion (CsA) and corticosteroids. The study was double-blind until all patients had completed 12 months, then open-label. By 36 months, graft loss occurred in 7. 2, 16. 7 and 10. 7 % {{of patients in}} the everolimus 1. 5, 3 mg/day, and MMF groups, respectively (p = 0. 0048 for everolimus 1. 5 mg/day vs. 3 mg/day); efficacy failure (biopsy-proven acute rejection (BPAR), graft loss, death or lost to follow-up) occurred in 33. 0, 38. 9 and 37. 2 % of patients (p = 0. 455 overall), respectively. Mortality and incidence of BPAR were comparable in all groups. Creatinine values were higher in everolimus groups, requiring a protocol amendment that recommended lower CsA exposure. Diarrhea, lymphocele, peripheral edema and hyperlipidemia were more common among everolimus-treated patients, whereas viral infections, particularly cytomegalovirus infection, increased in the MMF group. Overall safety and tolerability were better with MMF and everolimus 1. 5 mg/day than with everolimus 3 mg/day. In conclusion, at 36 months, an immunosuppressive regimen containing everolimus 1. 5 mg/day had equivalent patient, and graft survival and rejection rates compared with MMF in <b>de</b> <b>novo</b> renal transplant recipients, whereas everolimus 3 mg/day had inferior graft survival. Renal dysfunction in everolimus cohorts necessitates close monitoring. status: publishe...|$|R
40|$|Early {{initiation}} of everolimus with calcineurin inhibitor therapy {{has been shown}} to reduce the progression of cardiac allograft vasculopathy (CAV) in <b>de</b> <b>novo</b> heart transplant recipients. The effect of <b>de</b> <b>novo</b> everolimus therapy and early total elimination of calcineurin inhibitor therapy has, however, not been investigated and is relevant given the morbidity and lack of efficacy of current protocols in preventing CAV. This 12 -month multicenter Scandinavian <b>trial</b> randomized 115 <b>de</b> <b>novo</b> heart transplant recipients to everolimus with complete calcineurin inhibitor elimination 7 - 11 weeks after HTx or standard cyclosporine immunosuppression. Ninety-five (83 %) patients had matched intravascular ultrasound examinations at baseline and 12 months. Mean (± SD) recipient age was 49. 9 ± 13. 1 years. The everolimus group (n = 47) demonstrated significantly reduced CAV progression as compared to the calcineurin inhibitor group (n = 48) (ΔMaximal Intimal Thickness 0. 03 ± 0. 06 and 0. 08 ± 0. 12 mm, ΔPercent Atheroma Volume 1. 3 ± 2. 3 and 4. 2 ± 5. 0 %, ΔTotal Atheroma Volume 1. 1 ± 19. 2 mm(3) and 13. 8 ± 28. 0 mm(3) [all p-values ≤ 0. 01]). Everolimus patients also had a significantly greater decline in levels of soluble tumor necrosis factor receptor- 1 as compared to the calcineurin inhibitor group (p = 0. 02). These preliminary results suggest that an everolimus-based CNI-free can potentially be considered in suitable <b>de</b> <b>novo</b> HTx recipients...|$|R
40|$|INTRODUCTION: There is a {{continuing}} need for an immunosuppressive therapy that offers a high benefit-risk profile for renal transplant recipients, supporting long-term patient and graft survival while minimizing cumulative nephrotoxicity and other side effects. Belatacept, the first biological agent developed for primary maintenance immunosuppression, was recently approved for use in Europe. Belatacept combined with corticosteroids and a mycophenolic acid is indicated for prophylaxis of graft rejection in adults receiving renal transplant. Its use is contraindicated in Epstein-Barr virus seronegative or serostatus unknown patients due to increased risk of developing posttransplant lymphoproliferative disorder. AREAS COVERED: This review provides practical recommendations {{for the use of}} belatacept, based on safety and efficacy data from Phase II and Phase III clinical <b>trials</b> in <b>de</b> <b>novo</b> kidney transplant recipients. EXPERT OPINION: Treatment with belatacept is associated with improved long-term graft function, making belatacept an important option for prevention of kidney allograft rejection. Furthermore, efficacy and safety data over several years of therapy suggest that belatacept is particularly suitable for long-term immunosuppression, and the selective targeting offered by belatacept may help avoid some of the non-specific chronic safety risks associated with calcineurin inhibitors and steroids. Future studies will clarify the optimal regimen for belatacept usage...|$|R
50|$|The {{result of}} the trial was a {{conviction}} and sentence to imprisonment for five years. On appeal, the petitioner urged that the District Court had erred in refusing to permit a <b>trial</b> <b>de</b> <b>novo</b> {{on the merits of}} his claimed exemption.|$|E
5000|$|A second court {{reorganization}} in 1992 {{greatly expanded}} the Juvenile Court Department and ended <b>trial</b> <b>de</b> <b>novo</b> in the District Court Department. It also replaced Administrative Justices with Chief Justices {{and created a}} central office headed by the Chief Justice for Administration and Management.|$|E
50|$|In {{some types}} of cases (for example, if the {{original}} trial court was not a court of record) or in some legal systems, if the losing {{party to a case}} appeals, then the appellate court itself will hold a new trial, known as a <b>trial</b> <b>de</b> <b>novo.</b>|$|E
40|$|Background: Americans see {{clinical}} research as important, with over 15 million American residents participating in NIH-sponsored studies in 2008 and growing yearly. Methods: Documents reporting NIH supported Clinical Research projects were reviewed. Results: When {{compared with other}} studies, the number of interventional Phase III and Phase IV trials have decreased from 20 % to 4. 4 % from 1994 - 2008. Conclusions: This finding most likely has occurred for several reasons. One {{reason is that the}} physician lacks an infrastructure for designing and carrying out trials. This lack is because of an absence of a coordinated effort to train clinical trialists. It is clear that the Nation needs a more purposeful approach to developing and maintaining the infrastructure for designing and conducting clinical <b>trials.</b> Building it <b>de</b> <b>novo</b> <b>trial</b> by trial is profoundly inefficient, to say nothing about time consuming and error prone...|$|R
40|$|The {{association}} of cyclosporine A (CsA) with everolimus can exert synergistic {{effects on the}} alloimmune response. CsA inhibits the synthesis of interleukin- 2 while everolimus inhibits the response to interleukin- 2. Moreover, the interaction with CsA increases the bioavailability of everolimus (1). These data {{suggest that it is}} possible to reduce the doses of both drugs when given in combination. Previously, we reported the 1 -year results of a randomized <b>trial</b> in 285 <b>de</b> <b>novo</b> renal transplants, 278 from deceased donors (2). Patients of group A received low-concentration CsA (C 2 maintenance levels 350 – 500 ng/mL) plus everolimus (C 0 levels 3 – 8 ng/mL), while patients of group B received very low-concentration CsA (C 2 maintenance levels 150 – 300 ng/mL) and everolimus at higher target levels (C 0 8 – 12 ng/mL). One-year graft survival rate was better in group B (98...|$|R
40|$|The {{diagnosis}} of therapy-related myeloid leukemia (t-MDS/t-AML) identifies {{a group of}} high-risk patients with multiple and varied poor prognostic features. These neoplasms {{are thought to be}} the direct conse-quence of mutational events induced by cytotoxic therapy. Their outcomes have historically been poor compared with those of people who develop acute myeloid leukemia (AML) <b>de</b> <b>novo.</b> The question arises whether a {{diagnosis of}} t-AML per se indicates a poor prognosis, or whether their bad outcomes result from other clinical and biologic characteristics. Because of lingering damage from prior cytotoxic therapy and, in some cases, the persistence of their primary disorder, patients with t-AML are often poor candidates for intensive AML therapy. The spectrum of cytogenetic abnormalities in t-AML is similar to <b>de</b> <b>novo</b> AML, but the frequency of unfavorable cytogenetics, such as a complex karyotype or deletion or loss of chromo-somes 5 and/or 7, is higher in t-AML. Survival varies according to cytogenetic risk group, with better outcomes observed in patients with t-AML with favorable-risk karyotypes. Treatment recommenda-tions should be based on performance status and karyotype. Patients with t-AML should be enrolled on front-line chemotherapy <b>trials,</b> appropriate for <b>de</b> <b>novo</b> AML patients with similar disease characteristics. Allogeneic hematopoietic cell transplantation can cure some patients with t-AML. Most important, the molecular and genetic differences that appear to determine the phenotype and the outcome of these patients need to be investigated further. What Further Therapy Would Yo...|$|R
